COVAXX Gets Supply Deals Worth US$2.8 Billion for Potential Covid-19 Vaccine

The U.S.-based company signed an agreement in September with Brazilian lab and hospital group DASA S.A. to conduct mid-to-late stage trials in Brazil for the vaccine.

RIO DE JANEIRO, BRAZIL - COVAXX, a unit of United Biomedical Inc, said on Thursday it has received purchase commitments totaling US$2.8 billion to deliver more than 140 million doses of its potential Covid-19 vaccine to developing countries, including Brazil, Peru and Ecuador.

The multitope peptide-based vaccine is currently in early-stage trials in Taiwan, lagging some of the frontrunners in the race to develop a safe and effective vaccine.

The U.S.-based company signed an agreement in September with Brazilian laboratory and hospital group DASA S.A. to conduct mid-to-late stage trials for . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?